Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.48 |
| ▸ | MC4R | P32245 | 2/20 | 0.46 |
| ▸ | MC5R | P33032 | 2/20 | 0.46 |
| ▸ | MC3R | P41968 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21169304 | 0.86 | OPRM1 (0.53) | OPRM1ALDH1A1MC4RMC5RMC3R | |
| SCHEMBL19002822 | 0.82 | OPRM1 (0.69) | OPRM1ALDH1A1MC4RMC5RMC3R | |
| SCHEMBL19049620 | 0.80 | OPRM1 (0.57) | OPRM1ALDH1A1MC4RMC5RMC3R | |
| SCHEMBL24943172 | 0.79 | OPRM1 (0.51) | OPRM1ALDH1A1MC4RMC5RMC3R | |
| SCHEMBL18997815 | 0.78 | SLC6A2 (0.55) | OPRM1ALDH1A1MC4RMC5RMC3R | |
| SCHEMBL23467892 | 0.78 | NSD2 (0.51) | OPRM1ALDH1A1LMNAKMT2A | |
| SCHEMBL21900761 | 0.75 | OPRM1 (0.53) | OPRM1ALDH1A1MC4RMC5RMC3R | |
| SCHEMBL6207029 | 0.71 | C5AR1 (0.47) | OPRM1ALDH1A1MC4RMC5RMC3R | |
| SCHEMBL6206609 | 0.70 | C5AR1 (0.46) | OPRM1ALDH1A1MC4RMC5RMC3R | |
| SCHEMBL14099804 | 0.70 | C5AR1 (0.46) | OPRM1ALDH1A1MC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | OPRM1 3875/4885ALDH1A1 2765/4885MC4R 2802/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | OPRM1 3875/4885ALDH1A1 2765/4885MC4R 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.